RECRUITING

Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group childcare centers and in staff who regularly work at the center. Participants will complete a health survey and provide one saliva sample for CMV PCR testing. In addition, infrastructure for the study will be developed (e.g. community engagement to build the network of centers, data pipelines, digital platform, sampling workflows) and participant sample collection at home will be piloted. These activities will inform the design of STAGE II.

Official Title

Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study: An Observational Study to Evaluate CMV Transmission and Immune Correlates of Viral Shedding Among Young Children in Early Education and Care Settings

Quick Facts

Study Start:2023-08-10
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06522880

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Day to 36 Months
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Laura Gibson, MD
CONTACT
5089813660
laura.gibson@umassmed.edu
Karen Del'Olio, MPH
CONTACT
5084718701
karen.del'olio@umassmed.edu

Principal Investigator

Laura Gibson, MD
PRINCIPAL_INVESTIGATOR
UMass Chan Medical School

Study Locations (Sites)

UMass Chan Medical School
Worcester, Massachusetts, 01655
United States

Collaborators and Investigators

Sponsor: University of Massachusetts, Worcester

  • Laura Gibson, MD, PRINCIPAL_INVESTIGATOR, UMass Chan Medical School

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-10
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2023-08-10
Study Completion Date2027-12-31

Terms related to this study

Keywords Provided by Researchers

  • cytomegalovirus
  • CMV
  • congenital cytomegalovirus
  • cCMV

Additional Relevant MeSH Terms

  • Cytomegalovirus Infections